Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Bristol-Myers Squibb (NY: BMY )

67.40 +0.42 (+0.63%)
Streaming Delayed Price Updated: 12:03 PM EDT, Mar 24, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Bristol-Myers Squibb

< Previous 1 2 3 4 5 6 7 8 9
...
34 35 Next >
3 Dirt-Cheap Stocks to Buy Sooner Rather Than Later
Procrastination could be problematic with these three bargain stocks. 
Via The Motley Fool
U.S. Food and Drug Administration (FDA) Accepts Supplemental New Drug Application for CAMZYOS® (mavacamten) in Symptomatic Obstructive Hypertrophic Cardiomyopathy to Reduce the Need for Septal Reduction Therapy
From Bristol Myers Squibb
Via Business Wire
New Data Reinforce Benefits Of Bristol Myers's Opdivo In Earlier Stages Of Melanoma
 
Via Benzinga
Bristol Myers Squibb Presents Data from CheckMate -76K Showing Opdivo (nivolumab) Reduced the Risk of Recurrence or Death by 58% Versus Placebo in Patients with Completely Resected Stage IIB or IIC Melanoma
From Bristol Myers Squibb
Via Business Wire
Bristol Myers Squibb Company: Too Cheap To Ignore
Since November 2018 Bristol Myers has been selling at a discount to not only its historical norms but historical market norms as well. 
Via Talk Markets
10 Health Care Stocks Whale Activity In Today's Session
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity... 
Via Benzinga
Merck Nears Breakout Point After October Surprise Good News
Dow component Merck is within 2% of an all-time high after rallying 7.30% in the past month. It got a boost from news about two new treatments. 
Via MarketBeat
Topics Stocks
Exposures US Equities
Why Legend Biotech's Shares Jumped 14.2% On Tuesday
The company presented news regarding early revenue figures for a multiple myeloma therapy it collaborated on. 
Via The Motley Fool
What Is Going on With AVEO Pharmaceuticals (AVEO) Stock Today?
AVEO stock jumped on the news that LG Chem will pay $15/share for Aveo Oncology and make it the centerpiece of a new oncology division. 
Via InvestorPlace
Salesforce Pops As Hedge Fund Starboard Discloses Stake In Software Maker
CRM stock popped after activist investor Starboard Value disclosed that it has taken a stake in the enterprise software maker. 
Via Investor's Business Daily
Jupiter Wellness's Potential New OTC Drug Could Put Some More Joy Back Into Breast Cancer Survivors' Lives
Breast cancer has surpassed lung cancer as the most commonly diagnosed cancer globally as of 2021, according to the American Cancer Society and the International Agency for Research on Cancer.  
Via Benzinga
Steady As She Goes With Healthcare Stocks
Favorable seasonality lies ahead for Q4 with a caveat of Q3 earnings reports. 
Via Talk Markets
3 Fast-Growing Medical Dividend Stocks
Sometimes, the strongest payout growth can be found among the future Dividend Aristocrats, not the current ones. 
Via The Motley Fool
Peering Into Bristol-Myers Squibb's Recent Short Interest
Bristol-Myers Squibb's (NYSE:BMY) short percent of float has risen 4.63% since its last report. The company recently reported that it has 24.18 million shares sold short, which is 1.13% of all regular... 
Via Benzinga
Got $5,000? These 2 Stocks Could Continue Beating the Bear Market.
These two stocks have solid fundamentals and are delivering strong results. 
Via The Motley Fool
The 7 Most Undervalued Value Stocks to Buy Now
Undervalued value stocks remain available even as investors have pivoted toward low-valuation stocks in a volatile year for markets. 
Via InvestorPlace
What 6 Analyst Ratings Have To Say About Bristol-Myers Squibb
Within the last quarter, Bristol-Myers Squibb (NYSE:BMY) has observed the following analyst ratings: 
Via Benzinga
Will Chart Analysts Notice Bad Omen on Bristol-Myers Squibb's Chart
If history is any guide, there may be trouble ahead for shares of Bristol-Myers Squibb (NYSE:BMY). A so-called "death cross" has formed on its chart and, not surprisingly, this could be bearish for the... 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For October 10, 2022
Upgrades 
Via Benzinga
Want to Buy the Dip? This Real Estate Stock Is a Smart Buy
This REIT specializes in office space for white-coat lab work that can't really be done at home. 
Via The Motley Fool
PureTech Health Confirms 'Possible' Merger With Nektar Therapeutics
 
Via Benzinga
Bristol Myers Squibb Announces Change to Earnings Conference Call Dial-In Information for Third Quarter 2022 Results Scheduled for October 26, 2022
From Bristol Myers Squibb
Via Business Wire
Israeli Ministry Of Health Clears Way For Human Trials Of AllocetraTM, A Proprietary Off-the-Shelf Immunotherapy For Solid Tumors
The Israeli Ministry of Health (MOH) approved a Phase I/II trial of Enlivex Therapeutics Ltd.’s (NASDAQ: ENLV) proprietary immunothera 
Via Benzinga
3 Stocks Savvy Investors Are Buying Hand Over Fist
These high-flying stocks are defying the bear market. 
Via The Motley Fool
Best Stocks 2022: Why Bristol-Myers Squibb (BMY) Stock Is a Clear Winner
There's a reason BMY stock is currently winning our Best Stocks for 2022 contest. Investors should buy BMY for value, safety and dividends. 
Via InvestorPlace
Best Stocks 2022: These 3 Factors Can Send Sonic Automotive (SAH) Stock Soaring in Q4
While Sonic Automotive isn’t in the lead for the top 10 best stocks ranking, SAH stock performs relatively well because of its fundamentals. 
Via InvestorPlace
Autolus Therapeutics Stock Jumps After Bristol Myers Pact For Safety Switch System
 
Via Benzinga
Autolus Therapeutics Announces Collaboration with Bristol Myers Squibb for Use of Autolus’ Proprietary Safety Switch System
From Autolus Therapeutics plc
Via Globe NewsWire
Large Cap Biopharmaceuticals: Core Holdings For Your Portfolio
Now that some clarity is apparent for drug pricing legislation you should have a few large-cap biopharmaceutical stocks in your portfolio. 
Via Talk Markets
These Stocks Are On The Radar After Biogen-Eisai's Surprising Alzheimer's Trial Win
 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9
...
34 35 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.